Get the Stockscreener App
10.69
0.09%
0.010
Pre-market:
10.67
-0.02
-0.19%
Evoke Pharma Inc stock is traded at $10.69, with a volume of 44,670.
It is up +0.09% in the last 24 hours and up +129.40% over the past month.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
See More
Previous Close:
$10.68
Open:
$10.67
24h Volume:
44,670
Relative Volume:
0.21
Market Cap:
$16.66M
Revenue:
$8.62M
Net Income/Loss:
$-6.15M
P/E Ratio:
-0.9692
EPS:
-11.03
Net Cash Flow:
$-5.32M
1W Performance:
+0.00%
1M Performance:
+129.40%
6M Performance:
+229.93%
1Y Performance:
+134.43%
1-Day Range:
$10.67
$10.70
1-Week Range:
$10.66
$10.75
52-Week Range:
$1.94
$10.79
Evoke Pharma Inc Stock (EVOK) Company Profile
Name
Evoke Pharma Inc
Sector
Phone
858-345-1494
Address
420 STEVENS AVENUE, SOLANA BEACH, CA
Compare EVOK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVOK
Evoke Pharma Inc
|
10.69 | 18.40M | 8.62M | -6.15M | -5.32M | -11.03 |
|
ZTS
Zoetis Inc
|
115.89 | 51.60B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.51B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.60 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.28 | 28.04B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.72 | 20.52B | 3.08B | 1.24B | 1.07B | 25.61 |
Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-22-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-05-19 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-08-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Oct-19-17 | Resumed | FBR & Co. | Buy |
| Mar-16-17 | Reiterated | Rodman & Renshaw | Buy |
| Jan-30-17 | Upgrade | Laidlaw | Neutral → Buy |
| Jan-05-17 | Upgrade | Rodman & Renshaw | Neutral → Buy |
| Dec-23-16 | Reiterated | Rodman & Renshaw | Neutral |
| Jul-19-16 | Reiterated | FBR Capital | Outperform |
| Jul-19-16 | Downgrade | Noble Financial | Buy → Hold |
| Jul-18-16 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Mar-16-16 | Initiated | Northland Capital | Outperform |
| Mar-14-16 | Reiterated | Ascendiant Capital Markets | Buy |
| Feb-17-16 | Resumed | FBR Capital | Outperform |
| Dec-03-14 | Reiterated | MLV & Co | Buy |
| Nov-07-14 | Initiated | MLV & Co | Buy |
| Apr-22-14 | Initiated | Laidlaw | Buy |
| Nov-19-13 | Initiated | Aegis Capital | Buy |
View All
Evoke Pharma Inc Stock (EVOK) Latest News
How Evoke Pharma Inc. stock reacts to bond yields2025 Volatility Report & Proven Capital Preservation Tips - newser.com
Why retail investors favor Evoke Pharma Inc. stockEarnings Recap Report & Real-Time Volume Triggers - newser.com
Evaluating Evoke Pharma Inc. with trendline analysisJuly 2025 Pullbacks & Proven Capital Preservation Tips - newser.com
KLEIN ROGER M Insider Trades - Nasdaq
How to read the order book for Evoke Pharma Inc.Earnings Performance Report & Free AI Powered Buy and Sell Recommendations - newser.com
Evoke Pharma Inc. (EVOK) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Evoke Pharma Inc. stock go up soon2025 Technical Patterns & Real-Time Buy Signal Notifications - newser.com
Using economic indicators to assess Evoke Pharma Inc. potential2025 Historical Comparison & Real-Time Stock Movement Alerts - newser.com
Will Evoke Pharma Inc. stock continue dividend increasesInsider Buying & Safe Capital Allocation Plans - newser.com
What drives Evoke Pharma Inc stock priceStock Buyback Updates & Rapid Portfolio Growth - earlytimes.in
Risk vs reward if holding onto Evoke Pharma Inc.2025 Year in Review & High Accuracy Trade Alerts - newser.com
Evoke Pharma Reports Increased Sales Amid Ongoing Losses - MSN
What valuation multiples suggest for Evoke Pharma Inc. stock2025 Price Momentum & Breakout Confirmation Alerts - newser.com
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger-COMP, HFWA, EVOK, and JTAI - The Malaysian Reserve
[SC TO-T] Evoke Pharma Inc Third-Party Tender Offer | EVOK SEC FilingForm SC TO-T - Stock Titan
Evoke Pharma’s Merger Uncertainty: Potential Risks to Business Operations and Financial Health - MSN
How currency fluctuations impact Evoke Pharma Inc. stockJuly 2025 Catalysts & Low Risk Growth Stock Ideas - newser.com
Identifying reversal signals in Evoke Pharma Inc.Weekly Trade Analysis & Stock Portfolio Risk Management - newser.com
Using Bollinger Bands to evaluate Evoke Pharma Inc.2025 Trading Volume Trends & Community Verified Swing Trade Signals - newser.com
Advanced analytics toolkit walkthrough for Evoke Pharma Inc.2025 Key Highlights & Technical Pattern Alert System - newser.com
Why Evoke Pharma Inc. stock is a value investor pickPrice Action & AI Driven Stock Movement Reports - newser.com
Price action breakdown for Evoke Pharma Inc.Portfolio Growth Summary & Intraday High Probability Setup Alerts - newser.com
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger-HBAN, AVDL, EVOK, and TRUE - The Malaysian Reserve
Quantitative breakdown of Evoke Pharma Inc. recent moveMarket Risk Summary & Daily Chart Pattern Signals - newser.com
How Evoke Pharma Inc. stock responds to policy changesJuly 2025 Momentum & Accurate Trade Setup Notifications - newser.com
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger-HBAN, AVDL, EVOK, and TRUE - Benzinga
Evoke Pharma (EVOK) Achieves Significant Revenue Growth in Q3 - GuruFocus
Evoke Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Evoke Pharma Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025 - MarketScreener
Form SC14D9CWritten communication relating to third party tender offer - ADVFN
[8-K] Evoke Pharma Inc Reports Material Event | EVOK SEC FilingForm 8-K - Stock Titan
Evoke Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Evoke Pharma Inc Stock (EVOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.17%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):